On Wednesday, the company released a statement saying that if the vaccine is found to be safe and effective, Johnson & Johnson would supply more than one billion doses globally through 2021.
"...we are continuing our efforts to build important global partnerships and invest in our vaccine production technology and manufacturing capabilities," said Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. "Our goal is to ensure we can deliver a vaccine to the world and protect people everywhere from this pandemic."
"The company is in discussions with the National Institutes of Allergy and Infectious Diseases with the objective to start the Phase 3 SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant, clinical trial ahead of its original schedule, pending the outcome of Phase 1 studies and approval of regulators," the statement reads.
Dr. Anthony Fauci sat down with TheStreet to talk about the coronavirus pandemic and Johnson & Johnson moving up the human trials of its COVID-19 vaccine candidate.
"Obviously, it's good news when you can move things along. One of the things that I believe we need to stress, particularly to the general public, that when we're moving along quickly, we're not doing it at all, at the expense of safety. That's always a major concern. Nor is it at the expense of scientific integrity. It's just that people are doing things, what we call, at risk. They're making steps. The risk is to the financial investment. The risk is not to the safety or to the scientific integrity of the study," Fauci told TheStreet.
You can follow Katherine Ross on Twitter at @byKatherineRoss.
Watch More of the Latest Videos from TheStreet and Jim Cramer
- Jim Cramer: Broadcom Is 'Greatest Value' of Semiconductor Stocks
- Jim Cramer: Advice for Investors Learning About the Stock Market
- TheStreet Explains: What Is Value Versus Growth in Stocks?
- How Magic Johnson Became the Business Icon He Is Today
- C-Suite: Why the Nikola Executive Team Is Taking Salaries of $1